Montelukast for obstructive sleep apnea

in a double-blind, randomized, placebo-controlled trial, a 12-week treatment with daily, oral montelukast effectively reduced the severity of obstructive sleep apnea (OSA) and the magnitude of the underlying adenoidal hypertrophy in children with non-severe OSA.